Indianapolis Colts Coach in Remission from Leukemia

Indianapolis Colts football coach Chuck Pagano, who was diagnosed with acute promyelocytic leukemia at the end of September, is already in "complete remission," according to his doctor Larry Cripe.

Results from both a white blood cell count as well as a bone marrow test came out normal following his sole treatment to date, a single round of chemotherapy. He will undergo another round of chemotherapy soon, followed by one more to complete his initial treatment.

Said interim coach Bruce Arians:

"His [blood cell] count was great. He knows that this next [round] is going to be really tough and we’re praying for him, and he’s going to be fine."

Acute promyelocytic leukemia is an extremely aggressive form of leukemia that requires immediate treatment upon diagnosis. People who go without treatment tend not to live longer than a few months.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap